Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. reported a Form 4 showing a grant of stock options covering 28,000 shares of common stock to a board designee associated with Perceptive Advisors. The options have an exercise price of $9.54 per share and expire on April 8, 2036, vesting monthly over 24 months while the optionee continues as a Service Provider.
LeonaBio, Inc. reported a Form 4 showing an option grant related to director compensation. Entities associated with director Joseph Edelman received a stock option covering 28,000 shares of common stock at an exercise price of $8.35 per share. The option vests on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, and expires on June 22, 2036. The grant was made under LeonaBio’s Outside Director Compensation Policy, with Perceptive entities having an indirect pecuniary interest through a management fee offset and disclaiming beneficial ownership except to that extent.
LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share. These options vest on the earlier of June 23, 2027 or just before the next annual stockholder meeting after June 22, 2026 and expire on June 22, 2036.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and are held as a direct ownership position.
According to the grant terms, these options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was issued under LeonaBio’s Outside Director Compensation Policy and was pro-rated based on her appointment to the board on May 5, 2026. After this grant, her reported option holdings from this award total 2,333 shares and expire on June 22, 2036.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting held after June 22, 2026. The award was granted under LeonaBio’s Outside Director Compensation Policy and pro-rated based on his board appointment on May 5, 2026.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. This is a compensation-related award rather than an open-market transaction.
LeonaBio, Inc. director Romano Kelly reported receiving a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholders’ meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy and reflects equity-based compensation rather than an open-market purchase or sale.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share. The options expire on June 22, 2036 and vest on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, under the company’s Outside Director Compensation Policy.
LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation. He was awarded 28,000 stock options to acquire LeonaBio common stock at an exercise price of $8.35 per share. The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, and expire on June 22, 2036. Following this grant, Johnson holds 28,000 options to purchase LeonaBio common stock directly.
LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation. The award covers 28,000 stock options for common stock with an exercise price of $8.35 per share, expiring on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Following this grant, she holds 28,000 derivative securities directly.